Search Results
Your search for ,dUe matches 5408 pages
Showing 301 - 350ASCO-CAP Guideline Update Confirms Previous Recommendations for HER2 Testing in Breast Cancer
In partnership with the College of American Pathologists (CAP), ASCO has affirmed findings from its 2018 practice guideline on the use of HER2 testing in breast cancer. Notably, the ASCO/CAP expert panel found there is currently no justification for a new designation of HER2 test results for...
Olaparib and Temozolomide in Advanced Uterine Leiomyosarcoma
In a phase II trial (NCI Protocol 10250) reported in the Journal of Clinical Oncology, Ingham et al found that the combination of olaparib and temozolomide showed activity in previously treated patients with advanced uterine leiomyosarcoma. Study Details In the multicenter trial, 22 evaluable...
Addition of SBRT to Immunotherapy in Advanced Solid Tumors
In the Belgian phase II CHEERS trial reported in JAMA Oncology, Spaas et al evaluated the addition of stereotactic body radiotherapy (SBRT) to anti–PD-1/PD-L1 immune checkpoint inhibitor therapy, with SBRT directed to a maximum of three lesions, in patients with advanced solid tumors. The...
Implementation of Pediatric Early Warning Systems in Resource-Limited Latin American Hospitals
In a study reported in The Lancet Oncology, Agulnik et al found that implementation of pediatric early warning systems resulted in reduced clinical deterioration event mortality among children with cancer in resource-limited hospitals in Latin America. Study Details The Proyecto Escala de...
Alfredo Quiñones-Hinojosa, MD: From Migrant Farm Worker to Neurosurgeon in Search of a Cure for Brain Cancer
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with neurosurgeon Alfredo Quiñones-Hinojosa, MD, FAANS, FACS, the James C. and Sarah K. Kennedy Dean of Research, Monica Flynn Jacoby Chair of Neurologic Surgery, and William J. and Charles...
Vemurafenib Plus Cobimetinib in Newly Diagnosed Patients With Papillary Craniopharyngiomas
In a small phase II trial reported in The New England Journal of Medicine, Priscilla K. Brastianos, MD, and colleagues found that the BRAF-MEK inhibitor combination of vemurafenib and cobimetinib produced an objective response in almost all patients with newly diagnosed papillary craniopharyngiomas ...
Addition of Atezolizumab to Cabozantinib in Renal Cell Carcinoma Progressing During or After Prior Immune Checkpoint Inhibition
In the phase III CONTACT-03 trial reported in The Lancet, Sumanta Pal, MD, FASCO, and colleagues found that the addition of atezolizumab to cabozantinib did not improve outcomes in patients with renal cell carcinoma whose disease progressed on or after prior immune checkpoint inhibitor treatment....
Lazertinib vs Gefitinib in the First-Line Treatment of EGFR-Mutated Advanced NSCLC
In a phase III trial (LASER301) reported in the Journal of Clinical Oncology, Byoung Chul Cho, MD, PhD, and colleagues found that lazertinib improved progression-free survival vs gefitinib in the first-line treatment of EGFR-mutated advanced non–small cell lung cancer (NSCLC). As stated by the...
Academically Developed BCMA-Directed CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
In an interim analysis of a Spanish pilot trial (CARTBCMA-HCB-01) reported in The Lancet Oncology, Oliver-Caldés et al found that an academically developed B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, ARI0002h, showed activity in patients with relapsed...
Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC
In the Spanish phase II NADIM II trial reported in The New England Journal of Medicine, Mariano Provencio, MD, PhD, and colleagues found that the addition of nivolumab to platinum-based chemotherapy improved pathologic complete response (pCR) rates among patients with resectable stage IIIA or IIIB...
First-Line Systemic Treatment Strategies for Initially Unresectable Colorectal Cancer Liver Metastases
In the Dutch Colorectal Cancer Group phase III CAIRO5 study reported in The Lancet Oncology, Bond et al investigated first-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases. The researchers found that FOLFOXIRI (leucovorin, fluorouracil,...
First-Line Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
As reported in the Journal of Clinical Oncology by O’Donnell et al, findings in a cohort of the phase Ib/II EV-103/KEYNOTE-869 study showed durable responses with first-line enfortumab vedotin-ejfv plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial...
Multicancer Early Detection Test in Symptomatic Patients Referred From Primary Care
In a prospective study (SYMPLIFY) reported in The Lancet Oncology, Nicholson et al found that a circulating tumor DNA methylation-based multicancer early detection diagnostic test showed promise in predicting a diagnosis of cancer in symptomatic patients referred from primary care for...
Amcenestrant vs Standard Endocrine Therapy in ER-Positive, HER2-Negative Advanced Breast Cancer
In the phase II AMEERA-3 trial reported in the Journal of Clinical Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that the selective estrogen receptor degrader amcenestrant did not improve progression-free survival vs physician’s choice of endocrine therapy in patients with estrogen...
Children of Parents With a History of Cancer May Experience Housing, Food, and Financial Hardship, as Well as Delays in Medical Care
Children of parents with a history of cancer are more likely to face housing and food insecurity and delayed medical care due to a lack of transportation compared to children without a parental history of cancer, according to a study published by Zheng et al in JAMA Network Open. Among these...
Pembrolizumab/Olaparib vs Next-Generation Hormonal Agents in Previously Treated Patients With Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Emmanuel S. Antonarakis, MD, and colleagues, the phase III KEYLYNK-010 trial has shown no improvement in survival outcomes with pembrolizumab/olaparib vs a next-generation hormonal agent (abiraterone or enzalutamide) in previously treated patients...
Role of Chemotherapy in Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Radiotherapy
In an updated individual patient data network meta-analysis reported in The Lancet Oncology, Petit et al found that the treatment approach with the highest overall survival benefit among patients with nonmetastatic nasopharyngeal carcinoma treated with radiotherapy was induction chemotherapy with...
Certain Cancers Will Likely Rise Exponentially Because of COVID-19 Screening Delays, Study Predicts
Delays in cancer screening during the COVID-19 pandemic will likely cause a significant increase in cancer cases that could have been caught earlier with screening. These cases may now be diagnosed at later stages, placing an increased burden on an already-strained health-care system, according to...
Immune Checkpoint Inhibitors Show Promise for People Living With HIV
New research involving people living with HIV treated with immune checkpoint inhibitors has provided valuable insights into the safety and efficacy of immunotherapy in this historically excluded population, according to data published in the Journal of Clinical Oncology.1 The real-world data...
First-Line Nivolumab/Ipilimumab Followed by Nivolumab in a Clinically Diverse Population With Unresectable Stage III or IV Melanoma
In the phase IIIb CheckMate 401 trial reported in the Journal of Clinical Oncology, Reinhard Dummer, MD, and colleagues described outcomes with first-line nivolumab/ipilimumab followed by nivolumab in a clinically diverse population of patients with unresectable stage III or IV melanoma, including...
Adjuvant Cisplatin/Gemcitabine vs Cisplatin/Fluorouracil After Chemoradiotherapy for Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Liu et al found that adjuvant cisplatin/gemcitabine improved progression-free survival vs cisplatin/fluorouracil following chemoradiotherapy in previously untreated patients with N2 or N3 nasopharyngeal carcinoma. Study Details In the...
VISION Trial: Health-Related Quality of Life With the Addition of Lu-177 Vipivotide Tetraxetan to Standard of Care in Patients With Advanced Prostate Cancer
In an analysis from the phase III VISION trial reported in The Lancet Oncology by Karim Fizazi, MD, PhD, and colleagues, the addition of lutetium (Lu-177) vipivotide tetraxetan to standard of care was associated with improved health-related quality of life in patients with prostate-specific...
Patient-Reported Outcomes From the PROSPECT Trial: Neoadjuvant FOLFOX vs Chemoradiation for Locally Advanced Rectal Cancer
In an analysis from the PROSPECT trial (Alliance N1048) reported in the Journal of Clinical Oncology, Ethan Basch, MD, MSc, FASCO, and colleagues identified patient-reported outcome patterns among those receiving neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin) or pelvic chemoradiation...
Noncovalent BTK Inhibitor Pirtobrutinib in Patients With Mantle Cell Lymphoma Previously Treated With Covalent BTK Inhibitors
In the phase I/II BRUIN trial reported in the Journal of Clinical Oncology, Michael Wang, MD, and colleagues found that the noncovalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib produced durable responses in patients with mantle cell lymphoma who were previously treated...
Endocrine Therapy Switch With or Without Ribociclib After Disease Progression on Endocrine Therapy and CDK4/6 Inhibition for Metastatic Breast Cancer
In the phase II MAINTAIN trial reported in the Journal of Clinical Oncology, Kevin Kalinsky, MD, MS, and colleagues found that a switch in endocrine therapy plus continued CDK4/6 inhibitor treatment with ribociclib was associated with improved progression-free survival in patients with hormone...
Cancer Survivors With Transportation Barriers to Care May Also Experience Financial Hardship, Food Insecurity, and Delays in Timely Care
Investigators have found that many U.S. cancer survivors with transportation barriers to care also reported struggling financially and experiencing additional barriers to timely care, according to new findings presented by Jiang et al at the 2023 ASCO Annual Meeting (Abstract 6534). Study Methods...
Study Finds T-DXd Effectively Treats HER2-Expressing Cancers, Regardless of Tumor Location
According to the findings of the international phase II DESTINY-PanTumor02 study presented by Funda Meric-Bernstam, MD, and colleagues at the 2023 ASCO Annual Meeting, fam-trastuzumab deruxtecan-nxki (T-DXd) is an effective treatment option for people with difficult-to-treat, HER2-expressing solid...
Nivolumab May Reduce Risk of Disease Progression or Death in Previously Untreated Patients With Hodgkin Lymphoma Compared to Brentuximab Vedotin
The immune checkpoint inhibitor nivolumab plus chemotherapy significantly reduced the risk of disease progression and disease-related death compared with standard treatment with the CD30-targeted drug brentuximab vedotin plus chemotherapy in pediatric and adult patients with previously untreated...
Patients Who Practice Qigong May Be Able to Improve Their Cancer-Related Fatigue
Researchers have found that patients with cancer-related fatigue who practiced qigong may have demonstrated clinically significant improvements in their fatigue burden after 10 weeks, according to a new study published by Zimmerman et al in Integrative Cancer Therapies. The findings revealed that...
Incidence of Colorectal, Lung, and Breast Cancers May Be Rising Due to COVID-19–Related Screening Delays
Delays in cancer screenings during the COVID-19 pandemic may have resulted in lower reported incidences of colorectal, lung, and breast cancers, reflecting potentially high rates of undiagnosed cancer and later-stage diagnoses, according to a new study published by Romatoski et al in the Journal of ...
Addition of First-Line Dalpiciclib to Letrozole or Anastrozole in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In an interim analysis of a Chinese phase III trial (DAWNA-2) reported in The Lancet Oncology, Zhang et al found that the addition of the CDK4/6 inhibitor dalpiciclib to letrozole or anastrozole improved progression-free survival as first-line treatment in patients with advanced hormone...
Disparities in Cancer Care: A Bangladeshi Perspective
The fight against cancer has made remarkable progress worldwide over the past decade. Through corporate investment in research and technology, the incidence of cancer and death rates in developed nations have steadily declined. The number of people living longer and fuller lives after a cancer...
Expert Point of View: Joshua G. Cohen, MD
Joshua G. Cohen, MD, Associate Clinical Professor in the Department of Surgery and Medical Director of the Orange County Gynecologic Cancer Program at City of Hope, Orange County, California, shared his thoughts on the ADAGIO trial with The ASCO Post. He noted that uterine serous carcinoma—the...
FDA Approves Avapritinib for Indolent Systemic Mastocytosis
On May 22, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis. Avapritinib is the first and only approved therapy for indolent systemic mastocytosis. Systemic mastocytosis is a rare ...
Addition of Panitumumab to Trifluridine/Tipiracil in Anti-EGFR Treatment Rechallenge in Refractory RAS Wild-Type Metastatic Colorectal Cancer
In the Italian phase II VELO trial reported in JAMA Oncology, Napolitano et al found that anti-EGFR treatment rechallenge with the addition of panitumumab to trifluridine/tipiracil improved progression-free survival in the third-line setting for patients with RAS wild-type metastatic colorectal...
Immune Checkpoint Inhibitors Show Promise for People Living With HIV
New research involving people living with HIV treated with immune checkpoint inhibitors has provided valuable insights into the safety and efficacy of immunotherapy in this historically excluded population, according to data published by El Zarif et al in the Journal of Clinical Oncology. The...
Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide in Patients With Metastatic Prostate Cancer Initiating ADT
In an analysis of the final results of two STAMPEDE platform phase III trials reported in The Lancet Oncology, Gerhardt Attard, PhD, and colleagues found that the addition of enzalutamide to abiraterone plus prednisolone did not appear to improve survival outcomes and was associated with worse...
Expert Point of View: Joshua G. Cohen, MD
Joshua G. Cohen, MD, Associate Clinical Professor in the Department of Surgery and Medical Director of the Orange County Gynecologic Cancer Program at City of Hope, Orange County, California, shared his thoughts on the ADAGIO trial with The ASCO Post. He noted that uterine serous carcinoma—the...
Study Finds Cancer-Related Emergency Department Visits Increased by 67%, Mainly Because of Uncontrolled Pain
Emergency department (ED) visits by patients with cancer increased by 67.1% between the start of 2012 and the end of 2019, compared with an increase of just 7.5% in cancer incidence, according to a recent study in JAMA Network Open.1 Factors identified as possible explanations for the...
ASCO Releases Guideline Updates for Stage IV NSCLC With and Without Driver Alterations
ASCO has updated two living guidelines on the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations with the inclusion of new evidence-based treatment recommendations.1,2 Among the updates, the guidelines add the recently approved RAS GTPase family...
Study Shows mRNA-Based Personalized Vaccine Plus Pembrolizumab Active in Melanoma for the First Time
The search for an effective cancer vaccine has been frustrating, but finally there may be light at the end of the tunnel. Adjuvant use of an investigational personalized mRNA vaccine (mRNA-4157) plus the PD-1 inhibitor pembrolizumab improved recurrence-free survival vs pembrolizumab alone in...
USPSTF Issues Draft Recommendation Statement on Screening for Breast Cancer: All Women Should Be Screened Every Other Year, Beginning at Age 40
On May 9, the U.S. Preventive Services Task Force (USPSTF) posted a draft recommendation statement on screening for breast cancer. The USPSTF now recommends that all women get screened for breast cancer every other year starting at age 40 years (this is a B grade recommendation, meaning the USPSTF...
Immunotherapy/Chemotherapy Combination Prolongs Survival in Advanced Biliary Tract Cancers
The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival in patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 trial presented at the 2023 American Association for Cancer...
First-in-Patient Study of PSMA-Targeted Fluorescent Tracer for Intraoperative Imaging of PSMA-Positive Prostate Cancer
In a single-institution Dutch phase IIa feasibility trial reported in The Lancet Oncology, Stibbe et al evaluated the pharmacokinetics and safety of the prostate-specific membrane antigen (PSMA)-targeted fluorescent tracer OTL78 in patients undergoing robot-assisted radical prostatectomy for...
Addition of Tislelizumab to Chemotherapy in First-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
As reported in The Lancet Oncology by Xu et al, an interim analysis of the phase III RATIONALE-306 trial has shown improved overall survival with the addition of the anti–PD-1 antibody tislelizumab to chemotherapy in the first-line treatment of advanced or metastatic esophageal squamous cell...
Economic Hardship May Be Predictive of Neurocognitive Outcomes in Pediatric Patients Undergoing Radiation Therapy
Researchers have found that pediatric patients with cancer undergoing radiation therapy may experience greater baseline and long-term neurocognitive outcomes when they have supportive environments compared with those who live in neighborhoods with economic hardship, according to a new study...
Remote Outreach May Increase Uptake of and Adherence to Cancer Screenings in Females in Rural Settings
Females in rural areas may be six times more likely to receive timely breast, cervical, and colorectal cancer screenings with remote outreach that involves interactive education and follow-up support by telephone compared with females in rural areas who don’t have remote outreach, according to a...
In BRCA-Mutated Ovarian Cancer, Neoadjuvant Olaparib Feasible, Appears Effective in Pilot Study
Encouraging outcomes were achieved in patients with BRCA-mutated ovarian cancer who received neoadjuvant treatment with olaparib in a feasibility study led by Shannon N. Westin, MD, MPH, Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD...
Long-Term Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar vs Reference Trastuzumab in HER2-Positive Early Breast Cancer
In a secondary analysis of the phase III SB3-G31-BC trial, Pivot et al found that perioperative use of the trastuzumab biosimilar SB3 was associated with a similar cardiac safety profile and similar efficacy outcomes compared with reference trastuzumab after up to 6 years of follow-up in patients...
Study Investigates Prevalence of ‘Low-Value’ PSA Screening for Prostate Cancer in Older Patients
In a survey study reported in JAMA Network Open, Kalavacherla et al found a high prevalence of prostate-specific antigen (PSA) screening for prostate cancer among older patients than recommended for such screening in U.S. Preventive Services Task Force guidelines. The investigators stated: “The...
